ReviewInternational journal of antimicrobial agents2012
Invasive fungal infections in patients with cancer in the Intensive Care Unit.
Review in International journal of antimicrobial agents, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Guideline
- Identification of Invasive Aspergillosis in Electronic Health Records.Open forum infectious diseases · 2026Article
- Novel infection byInfection and immunity · 2026Article
- Effect of antibiotic combination on secondary invasive fungal infection in critically ill sepsis patients.BMC infectious diseases · 2026Article
- Fast-tracking fungal detection: a rapid flow cytometric method for the detection of yeasts in blood cultures.Frontiers in microbiology · 2026Article
- Antifungal Minimal Inhibitory Concentrations of Mold Isolates from Patients with Cancer; Single-Center Experience, 2018-2023.Journal of fungi (Basel, Switzerland) · 2025Article
- [S1 guideline: diagnosis and treatment of invasive pulmonary aspergillosis in critically ill/intensive care patients].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025Review
- High prevalence of azole resistance among environmentalFrontiers in microbiology · 2025Article
- Evaluation of epidemiological, clinical, and microbiological features of vulvovaginal candidiasis.GMS hygiene and infection control · 2025Article
- Invasive Fungal Infections in the Paediatric Intensive Care Unit: A Hong Kong Study.Current pediatric reviews · 2024Article
- Optimization of a DNA extraction protocol for improving bacterial and fungal classification based on Nanopore sequencing.Access microbiology · 2024Article
- The Prevalence and Risk Factors of Trichosporonosis at King Abdulaziz University Hospital.International journal of general medicine · 2024Article
- Fungal mechanisms of intracellular survival: what can we learn from bacterial pathogens?Infection and immunity · 2023Review
- Antibodies to Combat Fungal Infections: Development Strategies and Progress.Microorganisms · 2023Review
- Addressing Microbial Resistance Worldwide: Challenges over Controlling Life-Threatening Fungal Infections.Pathogens (Basel, Switzerland) · 2023Review
- Human Airway Epithelium Responses to Invasive Fungal Infections: A Critical Partner in Innate Immunity.Journal of fungi (Basel, Switzerland) · 2022Review
- Immunogenicity and protective efficacy of a pan-fungal vaccine in preclinical models of aspergillosis, candidiasis, and pneumocystosis.PNAS nexus · 2022Article
- Review
- Demographic and Socioeconomic Factors Associated with Fungal Infection Risk, United States, 2019.Emerging infectious diseases · 2022Review
- Mortality Trends in Risk Conditions and Invasive Mycotic Disease in the United States, 1999-2018.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Invasive fungal infections (IFIs) have emerged as a major cause of morbidity and mortality amongst critically ill patients. Cancer patients admitted to the Intensive Care Unit (ICU) have multiple risk factors for IFIs. The vast majority of IFIs in the ICU are due to Candida spp. The incidence of invasive candidiasis (IC) has increased over recent decades, especially in the ICU. A shift in the distribution of Candida spp. from Candida albicans to non-albicans Candida spp. has been observed both in ICUs and oncology units in the last two decades. Timely diagnosis of IC remains a challenge despite the introduction of new microbiology techniques. Delayed initiation of antifungal therapy is associated with increased mortality. Therefore, prediction rules have been developed and validated prospectively in order to identify those ICU patients at high risk for IC and likely to benefit from early treatment. These rules, however, have not been validated in cancer patients. Similarly, major clinical studies on the efficacy of newer antifungals typically do not include cancer patients. Despite the introduction of more potent and less toxic antifungals, mortality from IFIs amongst cancer patients remains high. In recent years, aspergillosis and mucormycosis have also emerged as significant causes of morbidity and mortality amongst ICU patients with haematological cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.